FDA grants breakthrough therapy designation to severe asthma medication

Organisation: Position: Deadline Date: Location:

Amgen and AstraZeneca have announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype.

Tezepelumab is a potential first-in-class medication that works by blocking thymic stromal lymphopoietin (TSLP), an epithelial cytokine that is involved in the initiation and persistence of airway inflammation. Inhibition of TSLP is thought to prevent the release of pro-inflammatory cytokines by immune cells resulting in the prevention of asthma exacerbations and improved asthma control. Biologic therapies currently on the market only target type 2 driven inflammation.

The designation was based on data from the Phase 2b PATHWAY trial that evaluated 3 doses of tezepelumab as add-on therapy in patients with a history of asthma exacerbations and uncontrolled asthma receiving inhaled corticosteroids/long-acting β-agonist with or without oral corticosteroids and additional asthma controllers vs placebo.

Data showed that treatment with tezepelumab led to significant reductions (62% [70mg every 4 weeks], 71% [210mg every 4 weeks], and 66% [280mg every 2 weeks]) in the annual asthma exacerbation rate vs placebo (P <.001 for all) in patients with severe asthma. This effect was seen regardless of baseline blood eosinophil count or other type 2 inflammatory biomarkers. Asthma-related effects, nasopharyngitis, headaches, and bronchitis were the most common adverse events associated with tezepelumab.

Tezepelumab is being investigated in the Phase 3 PATHFINDER clinical programme, which includes planned mechanistic and long-term safety trials.

EMPR material

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.